跳到正文
原文
Endpoints News 生物医药· Andrew Dunn·· 1 天前AI 评分36

nChroma Bio提前终止唯一临床试验并裁员50%

nChroma Bio stops its only clinical study early, lays off 50%

AI 导读

基因疗法公司nChroma Bio宣布提前终止其唯一正在进行的临床试验,同时裁减50%员工。两年前,两位波士顿地区生物技术公司CEO合并各自初创企业,希望在基因医学公司低迷的市场环境中求存。

正文

A cou­ple of years ago, two Boston-area biotech CEOs de­cid­ed to merge their star­tups, hop­ing to sur­vive a down mar­ket for ge­net­ic med­i­cine com­pa­nies. Jeff …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news